News | Stem Cell Therapies | February 09, 2016

Using Electrical Signals to Train the Heart’s Muscle Cells

Researchers demonstrate that electrical stimulation can regulate and synchronize the beating properties of nascent heart cells

cardiomyocytes, electrical stimulation, human stem cells, Columbia Engineering

Electrically conditioned human cardiomyocytes. Striated ultrastructure containing troponin ( stained in green) forms around cell nuclei (stained in blue.) Image courtesy of Benjamin Lee, Columbia Engineering

February 9, 2016 — Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle cells (cardiomyocytes) engineered from human stem cells aids their development and function. The team used electrical signals, designed to mimic those in a developing heart, to regulate and synchronize the beating properties of nascent cardiomyocytes, the cells that support the beating function of the heart. The study, led by Gordana Vunjak-Novakovic, The Mikati Foundation Professor of Biomedical Engineering and a professor of medical sciences (in medicine), was published online January 19 in Nature Communications.

Cardiovascular disease is one of the major health problems around the world, especially because the heart cannot repair itself: If cardiomyocytes are lost to injury or disease, they have only a minimal ability to regenerate. Scientists have been trying to develop ways to regenerate hearts by using cardiomyocytes grown from the patient’s cells taken from skin or blood.

To be successful, these cardiomyocytes need to respond to and integrate with the surrounding heart muscle. But, currently, the immaturity and resultant irregular beating of human cardiomyocytes derived from stem cells have limited their usefulness for regenerative medicine and biological research.

“We’ve made an exciting discovery,” said Vunjak-Novakovic. “We applied electrical stimulation to mature these cells, regulate their contractile function and improve their ability to connect with each other. In fact, we trained the cell to adopt the beating pattern of the heart, improved the organization of important cardiac proteins and helped the cells to become more adult-like. This preconditioning is an important step to generating robust cells that are useful for a wide range of applications including the study of cardiomyocyte biology, drug testing and stem cell therapy. And we think that our method could lead to the reduction of arrhythmia during cell-based heart regeneration.”

Vunjak-Novakovic worked with George Eng and Benjamin Lee, both of whom recently received their Ph.D. from the Department of Biomedical Engineering. They are also M.D. students and the study’s co-leading authors. The team grew human stem cell-derived cardiomyocytes and engineered them into three-dimensional structures. They then exposed these structures to electrical signals that mimicked those in a healthy heart — over just one week. They showed that this electrical stimulation increased cardiomyocyte connectivity and the regularity of muscle contraction.

The researchers plan to conduct fundamental studies of how the immature heart develops its beating function, and to investigate whether the “conditioned” cardiomyocytes will have the ability to seamlessly integrate with the heart muscle and provide a synchronized beating function.

“The heart is an organ of amazing complexity with about 3 billion cells that beat synchronously in response to electrical signals,” Vunjak-Novakovic observed. “Our ability to recapitulate biology using bioengineering tools continues to drive our work and to be a source of inspiration. We are frequently reminded that this may be the best time ever to pursue biomedical engineering research.”

Lee added, “As a student in both engineering and medicine, I am particularly interested in how electrically conditioned cardiomyocytes can be used in a clinical context.”

The study was a collaborative effort that combined the deep knowledge of tissue engineering and bioreactor design in Vunjak-Novakovic’s lab with the stem cell expertise of Gordon Keller's lab in Toronto, and the cardiomyocyte electrophysiology expertise of the Robert Kass and Richard Robinson labs at the Columbia University Medical Center.

It was funded by the National Institutes of Health (research grants and pre-doctoral fellowships) and the MD/PhD program at Columbia University. (NIH funding—grants HL076485, UH2 EB17103 and EB002520 to G.V.-N.; F30 HL112505 to G.E., and the New York State—grants CO26449 and C028119 to G.V.-N.)

For more information: www.nature.com/ncomms

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init